A Phase 2 interventional study of M5049 and M5049 in Coronavirus Disease 2019, sponsored by EMD Serono Research & Development Institute, Inc.. Completed at 21 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-06-06.
Sponsored by EMD Serono Research & Development Institute, Inc. (part of Merck KGaA, Darmstadt, Germany) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 317 studies in COVID-19 with a site in Brazil — 20 open to participants now, 28 under way, 9 of them phase 3. COVID-19 · Brazil.
Among the 317 studies in COVID-19 with a site in Brazil, this one is the 154th largest by enrollment of the 263 interventional ones that give a count, is one of 153 that started in 2020, is one of 56 in phase 2, and was the 72nd registered.
7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.
Browse COVID-19 studies →20 of the 317 studies in COVID-19 with a site in Brazil are open now. Recruiting first, the newest first:
Douglas D. Fraser · Sites in Brazil, United States, Canada and 4 more countries
Ages 18–65
Pfizer · Sites in Brazil, United States, Argentina and 15 more countries
Ages 18+
Pfizer · Sites in Brazil, United States, Argentina and 16 more countries
Ages 12+
Merck Sharp & Dohme LLC · Sites in Brazil, United States, Argentina and 21 more countries
Ages 18+
Universidade Federal do Rio Grande do Norte · Sites in Brazil
Ages 18–55 · Healthy volunteers
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
317 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 104 · Phase 3 109 · Phase 4 14
First in 2015; this study’s year is marked. 153 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 149 is above the median of 102 across 4,366 interventional studies indexed under COVID-19.
Median enrollment 205 across the 263 interventional studies, 598 across the 54 observational. Of the 215 that completed or were terminated, 82 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
110 of 317 have an industry lead sponsor. The 10 most frequent:
This study is registered under EMD Serono Research & Development Institute, Inc., one of the names counted as Merck KGaA, Darmstadt, Germany. Under that name alone:
EMD Serono Research & Development Institute, Inc. is the lead sponsor of 87 studies on the registry; 8 are open to participants now.
Of its 47 completed or terminated interventional studies of FDA-regulated products, 38 (81%) have results posted.
Merck KGaA, Darmstadt, Germany has 1 study filed under COVID-19 — fewer than ten, so there is no comparison to draw.
5 of the studies in COVID-19 with a site in Brazil that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT05041907University of OxfordFinding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) | 2027-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 317 studies in COVID-19 with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study will evaluate the safety and efficacy of orally-administered M5049 in Coronavirus disease 2019 (COVID-19) pneumonia participants who are hospitalized but not on mechanical ventilation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: M5049
Drug: M5049
Drug: Placebo
Time to Recovery
Time to recovery was defined as the time from first dose (Day 1) to first occurrence of World Health Organization (WHO) 9-point ordinal scale 3 or less. The scoring is assessed with the following ordinal scale: 0. Uninfected: no clinical or virological evidence of infection; 1. Ambulatory: no limitation of activities; 2. Ambulatory: limitation of activities; 3. Hospitalized, mild disease: hospitalized, no oxygen therapy; 4. Hospitalized, mild disease: oxygen by mask or nasal prongs; 5. Hospitalized, severe disease: noninvasive ventilation or high-flow oxygen; 6. Hospitalized, severe disease: intubation and mechanical ventilation; 7. Hospitalized, severe disease: ventilation plus additional organ support for example: vasopressors or Extracorporeal membrane oxygenation (ECMO); 8. Death.
Time frame: Day 1 through Day 28
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Adverse Events of Special Interests (AESIs), TEAEs Leading to Treatment Discontinuation and Serious TEAEs (SAEs) According to NCI-CTCAE Version 5.0
Adverse Event (AE) was defined any untoward medical occurrence in a participant administered with a study drug, which does not necessarily had a causal relationship with this treatment. Serious AE was defined AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAEs: TEAEs was defined as events with onset date or worsening during the on treatment period. TEAEs included serious TEAEs and non-serious TEAEs.
Time frame: Day 1 through Day 60
Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameters
Laboratory investigation included hematology and biochemistry. The number of participants with clinically significant changes from baseline in laboratory parameters were reported. Clinical significance was determined by the investigator.
Time frame: Day 1 through Day 28
Number of Participants With Clinically Significant Changes From Baseline in 12-Lead Electrocardiogram (ECG) Measurements
12-lead ECG recordings included rhythm, heart rate (as measured by RR interval), PR interval, QRS duration, and QT interval. 12-lead ECG recordings were obtained after the participants have rested for at least 10 minutes in semisupine position. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in 12-lead ECG findings were reported.
Time frame: Day 1 through Day 28
Percentage of Participants Alive and Not Requiring Supplemental Oxygenation
The percentage of participants who were alive and did not require supplemental oxygenation or ventilatory support (including noninvasive or mechanical ventilation and Extra Corporeal Membrane Oxygenation \[ECMO\]) reported.
Time frame: Day 3, Day 7, Day 14, Day 21 and Day 28
Number of Participants in Each Clinical Status Category Based on 9-Point Ordinal Scale
Clinical status was based on data collected on the 'Ordinal Scale for Clinical Status and is assessed with the following ordinal scale: 0. Uninfected: no clinical or virological evidence of infection; 1. Ambulatory: no limitation of activities; 2. Ambulatory: limitation of activities; 3. Hospitalized, mild disease: hospitalized, no oxygen therapy; 4. Hospitalized, mild disease: oxygen by mask or nasal prongs; 5. Hospitalized, severe disease: noninvasive ventilation or high-flow oxygen; 6. Hospitalized, severe disease: intubation and mechanical ventilation; 7. Hospitalized, severe disease: ventilation plus additional organ support for example: vasopressors or ECMO; 8. Death.
Time frame: Baseline, Day 2, Day 3, Day 4, Day 5, Day 7, Day 10, Day 14, Day 21, Day 28, Day 44, Day 60
Time to Reach Peripheral Capillary Oxygen Saturation (SpO2) Greater Than or Equal to 94 Percent for at Least 24 Hours in Room Air
SpO2 is an estimate of the amount of oxygen in the blood. It is the percentage of hemoglobin containing oxygen compared to the total amount of hemoglobin in the blood (that is, oxygenated hemoglobin versus oxygenated and non-oxygenated hemoglobin). SpO2 measured by pulse oximetry. The time to SPO2 greater than or equal to (\>=) 94 percent (%) sustained for at least 24 hours in room air is reported in days.
Time frame: Day 1 through Day 28
Percentage of Participants With All-Cause Mortality
Percentage of Participants who died for any reason reported.
Time frame: Day 1 through Day 60
Time to Intensive Care Unit (ICU) Admission
Time to ICU admission was defined as the time from first dose (Day 1) to the date/time of ICU admission, or death, whichever occurs first, in days. Event-free survival function for time to event (ICU admission or death) estimated via Kaplan-Meier method.
Time frame: Day 1 through Day 28
Time to Non-Invasive Mechanical Ventilation
Time to non-invasive mechanical ventilation was defined as the time from first dose (Day 1) to the date/time of clinical status \>= 5, in days. Event-free survival function for time to event (Non-invasive mechanical ventilation or death) estimated via Kaplan-Meier method. Clinical status was based on data collected on the 'Ordinal Scale for Clinical Status and is assessed with the following ordinal scale: 0. Uninfected: no clinical or virological evidence of infection; 1. Ambulatory: no limitation of activities; 2. Ambulatory: limitation of activities; 3. Hospitalized, mild disease: hospitalized, no oxygen therapy; 4. Hospitalized, mild disease: oxygen by mask or nasal prongs; 5. Hospitalized, severe disease: noninvasive ventilation or high-flow oxygen; 6. Hospitalized, severe disease: intubation and mechanical ventilation; 7. Hospitalized, severe disease: ventilation plus additional organ support for example: vasopressors, and ECMO; 8. Death
Time frame: Day 1 through Day 28
Time to Invasive Mechanical Ventilation
Time to invasive mechanical ventilation was defined as the time from first dose (Day 1) to the date/time of clinical status \>= 6, in days. Event-free survival function for time to event (invasive mechanical ventilation or death) estimated via Kaplan-Meier method. Clinical status was based on data collected on the 'Ordinal Scale for Clinical Status and is assessed with the following ordinal scale: 0. Uninfected: no clinical or virological evidence of infection; 1. Ambulatory: no limitation of activities; 2. Ambulatory: limitation of activities; 3. Hospitalized, mild disease: hospitalized, no oxygen therapy; 4. Hospitalized, mild disease: oxygen by mask or nasal prongs; 5. Hospitalized, severe disease: noninvasive ventilation or high-flow oxygen; 6. Hospitalized, severe disease: intubation and mechanical ventilation; 7. Hospitalized, severe disease: ventilation plus additional organ support for example: vasopressors, and ECMO; 8. Death.
Time frame: Day 1 through Day 28
Total Length of Stay in Intensive Care Unit (ICU)
Total days in the ICU was defined as the sum, for all ICU admissions, of the time from ICU admission to the date of ICU discharge, in days.
Time frame: Day 1 through Day 60
Total Length of Hospitalization Stay
Total days in the hospital was defined as the sum, for all hospitalization events, of the time from first dose to the date of hospital discharge in days.
Time frame: Day 1 through Day 60
Time to Hospital Discharge
The time to hospital discharge, defined as the time from first dose (Day 1) to the date of first hospitalization discharge, in days.
Time frame: Day 1 through Day 60
Percent Change From Baseline in Inflammatory Biomarkers Over Time
C-Reactive Protein, D-Dimer and Ferritin inflammatory biomarkers were analyzed for this study. Percent Change From Baseline in Inflammatory Biomarkers Over Time were reported here.
Time frame: Baseline, Day 3, Day7, Day 10, Day 14 and Day 28
Percent Change From Baseline in Serum Cytokine Biomarkers
Interleukin 6 and Interleukin 8 serum cytokine biomarkers were analyzed. Percent Change From Baseline in Serum Cytokine Biomarkers were reported.
Time frame: Baseline, Day 3, Day7, Day 14 and Day 28
Percentage of Participants With Relapse
Relapse refers to rehospitalization due to worsening oxygenation, with either a positive result of any respiratory pathogenic nucleic acid test, or worsening lesions on chest imaging.
Time frame: Day 5 through Day 60
Percentage of Participants Who Are Re-Hospitalized
Percentage or participants who are re-hospitalized due to coronavirus disease 2019 (Covid-19) complications were reported.
Time frame: Day 5 through Day 60
Overall, 200 participants were screened for this study. Of which, 149 participants were randomized into the study.
| Milestone | Placebo | M5049 50 Milligram (mg) | M5049 100 mg |
|---|---|---|---|
| Started | 49 | 54 | 46 |
| Completed | 46 | 49 | 45 |
| Not completed | 3 | 5 | 1 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| Withdrew: Participant unable to attend day 60 visit | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 3 | 1 |
| Withdrew: Death | 2 | 1 | 0 |
Time to recovery was defined as the time from first dose (Day 1) to first occurrence of World Health Organization (WHO) 9-point ordinal scale 3 or less. The scoring is assessed with the following ordinal scale: 0. Uninfected: no clinical or virological evidence of infection; 1. Ambulatory: no limitation of activities; 2. Ambulatory: limitation of activities; 3. Hospitalized, mild disease: hospitalized, no oxygen therapy; 4. Hospitalized, mild disease: oxygen by mask or nasal prongs; 5. Hospitalized, severe disease: noninvasive ventilation or high-flow oxygen; 6. Hospitalized, severe disease: intubation and mechanical ventilation; 7. Hospitalized, severe disease: ventilation plus additional organ support for example: vasopressors or Extracorporeal membrane oxygenation (ECMO); 8. Death.
| Days | Placebo | M5049 50 Milligram (mg) | M5049 100 mg |
|---|---|---|---|
| Time to Recovery | 3.4 (2.7 to 4.9) | 3.7 (2.6 to 4.0) | 3.9 (2.0 to 4.8) |
Adverse Event (AE) was defined any untoward medical occurrence in a participant administered with a study drug, which does not necessarily had a causal relationship with this treatment. Serious AE was defined AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAEs: TEAEs was defined as events with onset date or worsening during the on treatment period. TEAEs included serious TEAEs and non-serious TEAEs.
| Participants | Placebo | M5049 50 Milligram (mg) | M5049 100 mg |
|---|---|---|---|
| Participants with any TEAE | 28 | 34 | 26 |
| Participants with any AESIs | 2 | 2 | 0 |
| Participants with TEAEs leading to discontinuation | 4 | 4 | 1 |
| Participants with Serious TEAEs | 9 | 5 | 1 |
Laboratory investigation included hematology and biochemistry. The number of participants with clinically significant changes from baseline in laboratory parameters were reported. Clinical significance was determined by the investigator.
| Participants | Placebo | M5049 50 Milligram (mg) | M5049 100 mg |
|---|---|---|---|
| Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameters | 0 | 0 | 0 |
12-lead ECG recordings included rhythm, heart rate (as measured by RR interval), PR interval, QRS duration, and QT interval. 12-lead ECG recordings were obtained after the participants have rested for at least 10 minutes in semisupine position. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in 12-lead ECG findings were reported.
| Participants | Placebo | M5049 50 Milligram (mg) | M5049 100 mg |
|---|---|---|---|
| Number of Participants With Clinically Significant Changes From Baseline in 12-Lead Electrocardiogram (ECG) Measurements | 1 | 0 | 0 |
The percentage of participants who were alive and did not require supplemental oxygenation or ventilatory support (including noninvasive or mechanical ventilation and Extra Corporeal Membrane Oxygenation \[ECMO\]) reported.
| Percentage of participants | Placebo | M5049 50 Milligram (mg) | M5049 100 mg |
|---|---|---|---|
| At Day 3 | 30.6 (19.5 to 44.5) | 27.5 (17.1 to 40.9) | 38.6 (25.7 to 53.4) |
| At Day 7 | 76.6 (62.8 to 86.4) | 83.3 (70.4 to 91.3) | 83.3 (69.4 to 91.7) |
| At Day 14 | 89.6 (77.8 to 95.5) | 89.8 (78.2 to 95.6) | 100.0 (92.0 to 100.0) |
| At Day 21 | 93.0 (81.4 to 97.6) | 93.8 (83.2 to 97.9) | 100.0 (91.8 to 100.0) |
| At Day 28 | 93.8 (83.2 to 97.9) | 98.0 (89.7 to 99.7) | 97.7 (88.2 to 99.6) |
Clinical status was based on data collected on the 'Ordinal Scale for Clinical Status and is assessed with the following ordinal scale: 0. Uninfected: no clinical or virological evidence of infection; 1. Ambulatory: no limitation of activities; 2. Ambulatory: limitation of activities; 3. Hospitalized, mild disease: hospitalized, no oxygen therapy; 4. Hospitalized, mild disease: oxygen by mask or nasal prongs; 5. Hospitalized, severe disease: noninvasive ventilation or high-flow oxygen; 6. Hospitalized, severe disease: intubation and mechanical ventilation; 7. Hospitalized, severe disease: ventilation plus additional organ support for example: vasopressors or ECMO; 8. Death.
| Participants | Placebo | M5049 50 Milligram (mg) | M5049 100 mg |
|---|---|---|---|
| Participants with Scale 0 at Baseline | 0 | 0 | 0 |
| Participants with Scale 1 at Baseline | 0 | 0 | 0 |
| Participants with Scale 2 at Baseline | 0 | 0 | 0 |
| Participants with Scale 3 at Baseline | 1 | 0 | 0 |
| Participants with Scale 4 at Baseline | 48 | 52 | 44 |
| Participants with Scale 5 at Baseline | 0 | 0 | 0 |
| Participants with Scale 6 at Baseline | 0 | 0 | 0 |
| Participants with Scale 7 at Baseline | 0 | 0 | 0 |
| Participants with Scale 8 at Baseline | 0 | 0 | 0 |
| Participants with Scale 0 at Day 2 | 0 | 0 | 0 |
| Participants with Scale 1 at Day 2 | 1 | 0 | 0 |
| Participants with Scale 2 at Day 2 | 0 | 1 | 2 |
| Participants with Scale 3 at Day 2 | 9 | 12 | 13 |
| Participants with Scale 4 at Day 2 | 35 | 39 | 30 |
| Participants with Scale 5 at Day 2 | 3 | 0 | 1 |
| Participants with Scale 6 at Day 2 | 0 | 1 | 0 |
| Participants with Scale 7 at Day 2 | 0 | 0 | 0 |
| Participants with Scale 8 at Day 2 | 0 | 0 | 0 |
| Participants with Scale 0 at Day 3 | 0 | 0 | 0 |
| Participants with Scale 1 at Day 3 | 2 | 2 | 1 |
| Participants with Scale 2 at Day 3 | 1 | 3 | 2 |
| Participants with Scale 3 at Day 3 | 12 | 9 | 14 |
| Participants with Scale 4 at Day 3 | 29 | 36 | 26 |
| Participants with Scale 5 at Day 3 | 4 | 0 | 1 |
| Participants with Scale 6 at Day 3 | 1 | 1 | 0 |
| Participants with Scale 7 at Day 3 | 0 | 0 | 0 |
| Participants with Scale 8 at Day 3 | 0 | 0 | 0 |
| Participants with Scale 0 at Day 4 | 0 | 0 | 0 |
| Participants with Scale 1 at Day 4 | 0 | 1 | 0 |
| Participants with Scale 2 at Day 4 | 0 | 1 | 0 |
| Participants with Scale 3 at Day 4 | 14 | 16 | 11 |
| Participants with Scale 4 at Day 4 | 17 | 22 | 21 |
| Participants with Scale 5 at Day 4 | 5 | 1 | 0 |
| Participants with Scale 6 at Day 4 | 0 | 1 | 0 |
| Participants with Scale 7 at Day 4 | 1 | 0 | 0 |
| Participants with Scale 8 at Day 4 | 0 | 0 | 0 |
| Participants with Scale 0 at Day 5 | 0 | 1 | 0 |
| Participants with Scale 1 at Day 5 | 9 | 6 | 6 |
| Participants with Scale 2 at Day 5 | 4 | 5 | 4 |
| Participants with Scale 3 at Day 5 | 13 | 18 | 16 |
| Participants with Scale 4 at Day 5 | 11 | 14 | 14 |
| Participants with Scale 5 at Day 5 | 6 | 3 | 0 |
| Participants with Scale 6 at Day 5 | 0 | 1 | 0 |
| Participants with Scale 7 at Day 5 | 2 | 0 | 0 |
| Participants with Scale 8 at Day 5 | 0 | 0 | 0 |
| Participants with Scale 0 at Day 7 | 0 | 1 | 1 |
| Participants with Scale 1 at Day 7 | 15 | 16 | 15 |
| Participants with Scale 2 at Day 7 | 11 | 9 | 8 |
| Participants with Scale 3 at Day 7 | 10 | 14 | 11 |
| Participants with Scale 4 at Day 7 | 4 | 5 | 7 |
| Participants with Scale 5 at Day 7 | 5 | 2 | 0 |
| Participants with Scale 6 at Day 7 | 0 | 1 | 0 |
| Participants with Scale 7 at Day 7 | 2 | 0 | 0 |
| Participants with Scale 8 at Day 7 | 0 | 0 | 0 |
| Participants with Scale 0 at Day 10 | 5 | 2 | 2 |
| Participants with Scale 1 at Day 10 | 16 | 21 | 18 |
| Participants with Scale 2 at Day 10 | 8 | 4 | 7 |
| Participants with Scale 3 at Day 10 | 5 | 10 | 7 |
| Participants with Scale 4 at Day 10 | 5 | 2 | 1 |
| Participants with Scale 5 at Day 10 | 2 | 2 | 0 |
| Participants with Scale 6 at Day 10 | 0 | 1 | 0 |
| Participants with Scale 7 at Day 10 | 1 | 0 | 0 |
| Participants with Scale 8 at Day 10 | 1 | 0 | 0 |
| Participants with Scale 0 at Day 14 | 5 | 5 | 6 |
| Participants with Scale 1 at Day 14 | 26 | 25 | 23 |
| Participants with Scale 2 at Day 14 | 7 | 8 | 8 |
| Participants with Scale 3 at Day 14 | 5 | 6 | 7 |
| Participants with Scale 4 at Day 14 | 2 | 3 | 0 |
| Participants with Scale 5 at Day 14 | 0 | 1 | 0 |
| Participants with Scale 6 at Day 14 | 1 | 1 | 0 |
| Participants with Scale 7 at Day 14 | 0 | 0 | 0 |
| Participants with Scale 8 at Day 14 | 2 | 0 | 0 |
| Participants with Scale 0 at Day 21 | 8 | 8 | 7 |
| Participants with Scale 1 at Day 21 | 22 | 30 | 35 |
| Participants with Scale 2 at Day 21 | 9 | 7 | 1 |
| Participants with Scale 3 at Day 21 | 1 | 0 | 0 |
| Participants with Scale 4 at Day 21 | 0 | 2 | 0 |
| Participants with Scale 5 at Day 21 | 0 | 0 | 0 |
| Participants with Scale 6 at Day 21 | 0 | 1 | 0 |
| Participants with Scale 7 at Day 21 | 1 | 0 | 0 |
| Participants with Scale 8 at Day 21 | 2 | 0 | 0 |
| Participants with Scale 0 at Day 28 | 14 | 11 | 15 |
| Participants with Scale 1 at Day 28 | 24 | 35 | 24 |
| Participants with Scale 2 at Day 28 | 5 | 3 | 4 |
| Participants with Scale 3 at Day 28 | 2 | 1 | 0 |
| Participants with Scale 4 at Day 28 | 1 | 0 | 1 |
| Participants with Scale 5 at Day 28 | 0 | 0 | 0 |
| Participants with Scale 6 at Day 28 | 0 | 0 | 0 |
| Participants with Scale 7 at Day 28 | 0 | 0 | 0 |
| Participants with Scale 8 at Day 28 | 2 | 1 | 0 |
| Participants with Scale 0 at Day 44 | 17 | 17 | 22 |
| Participants with Scale 1 at Day 44 | 23 | 30 | 20 |
| Participants with Scale 2 at Day 44 | 4 | 4 | 1 |
| Participants with Scale 3 at Day 44 | 2 | 0 | 0 |
| Participants with Scale 4 at Day 44 | 0 | 0 | 0 |
| Participants with Scale 5 at Day 44 | 0 | 0 | 0 |
| Participants with Scale 6 at Day 44 | 0 | 0 | 0 |
| Participants with Scale 7 at Day 44 | 0 | 0 | 0 |
| Participants with Scale 8 at Day 44 | 2 | 1 | 0 |
| Participants with Scale 0 at Day 60 | 18 | 17 | 22 |
| Participants with Scale 1 at Day 60 | 24 | 31 | 22 |
| Participants with Scale 2 at Day 60 | 3 | 2 | 1 |
| Participants with Scale 3 at Day 60 | 0 | 0 | 0 |
| Participants with Scale 4 at Day 60 | 0 | 0 | 0 |
| Participants with Scale 5 at Day 60 | 0 | 0 | 0 |
| Participants with Scale 6 at Day 60 | 0 | 0 | 0 |
| Participants with Scale 7 at Day 60 | 0 | 0 | 0 |
| Participants with Scale 8 at Day 60 | 2 | 1 | 0 |
SpO2 is an estimate of the amount of oxygen in the blood. It is the percentage of hemoglobin containing oxygen compared to the total amount of hemoglobin in the blood (that is, oxygenated hemoglobin versus oxygenated and non-oxygenated hemoglobin). SpO2 measured by pulse oximetry. The time to SPO2 greater than or equal to (\>=) 94 percent (%) sustained for at least 24 hours in room air is reported in days.
| Days | Placebo | M5049 50 Milligram (mg) | M5049 100 mg |
|---|---|---|---|
| Time to Reach Peripheral Capillary Oxygen Saturation (SpO2) Greater Than or Equal to 94 Percent for at Least 24 Hours in Room Air | 4.7 (2.8 to 6.9) | 4.8 (3.2 to 5.9) | 5.0 (3.9 to 9.0) |
Percentage of Participants who died for any reason reported.
| Percentage of participants | Placebo | M5049 50 Milligram (mg) | M5049 100 mg |
|---|---|---|---|
| Percentage of Participants With All-Cause Mortality | 4.1 (1.1 to 13.7) | 1.9 (0.3 to 9.8) | 0.0 (0.0 to 7.7) |
Time to ICU admission was defined as the time from first dose (Day 1) to the date/time of ICU admission, or death, whichever occurs first, in days. Event-free survival function for time to event (ICU admission or death) estimated via Kaplan-Meier method.
| Days | Placebo | M5049 50 Milligram (mg) | M5049 100 mg |
|---|---|---|---|
| Time to Intensive Care Unit (ICU) Admission | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Time to non-invasive mechanical ventilation was defined as the time from first dose (Day 1) to the date/time of clinical status \>= 5, in days. Event-free survival function for time to event (Non-invasive mechanical ventilation or death) estimated via Kaplan-Meier method. Clinical status was based on data collected on the 'Ordinal Scale for Clinical Status and is assessed with the following ordinal scale: 0. Uninfected: no clinical or virological evidence of infection; 1. Ambulatory: no limitation of activities; 2. Ambulatory: limitation of activities; 3. Hospitalized, mild disease: hospitalized, no oxygen therapy; 4. Hospitalized, mild disease: oxygen by mask or nasal prongs; 5. Hospitalized, severe disease: noninvasive ventilation or high-flow oxygen; 6. Hospitalized, severe disease: intubation and mechanical ventilation; 7. Hospitalized, severe disease: ventilation plus additional organ support for example: vasopressors, and ECMO; 8. Death
| Days | Placebo | M5049 50 Milligram (mg) | M5049 100 mg |
|---|---|---|---|
| Time to Non-Invasive Mechanical Ventilation | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Time to invasive mechanical ventilation was defined as the time from first dose (Day 1) to the date/time of clinical status \>= 6, in days. Event-free survival function for time to event (invasive mechanical ventilation or death) estimated via Kaplan-Meier method. Clinical status was based on data collected on the 'Ordinal Scale for Clinical Status and is assessed with the following ordinal scale: 0. Uninfected: no clinical or virological evidence of infection; 1. Ambulatory: no limitation of activities; 2. Ambulatory: limitation of activities; 3. Hospitalized, mild disease: hospitalized, no oxygen therapy; 4. Hospitalized, mild disease: oxygen by mask or nasal prongs; 5. Hospitalized, severe disease: noninvasive ventilation or high-flow oxygen; 6. Hospitalized, severe disease: intubation and mechanical ventilation; 7. Hospitalized, severe disease: ventilation plus additional organ support for example: vasopressors, and ECMO; 8. Death.
| Days | Placebo | M5049 50 Milligram (mg) | M5049 100 mg |
|---|---|---|---|
| Time to Invasive Mechanical Ventilation | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Total days in the ICU was defined as the sum, for all ICU admissions, of the time from ICU admission to the date of ICU discharge, in days.
| Days | Placebo | M5049 50 Milligram (mg) | M5049 100 mg |
|---|---|---|---|
| Total Length of Stay in Intensive Care Unit (ICU) | 7.1 (1 to 17) | 10.2 (3 to 23) | 3.7 (2 to 6) |
Total days in the hospital was defined as the sum, for all hospitalization events, of the time from first dose to the date of hospital discharge in days.
| Days | Placebo | M5049 50 Milligram (mg) | M5049 100 mg |
|---|---|---|---|
| Total Length of Hospitalization Stay | 7.0 (2 to 41) | 6.0 (2 to 29) | 6.0 (2 to 17) |
The time to hospital discharge, defined as the time from first dose (Day 1) to the date of first hospitalization discharge, in days.
| Days | Placebo | M5049 50 Milligram (mg) | M5049 100 mg |
|---|---|---|---|
| Time to Hospital Discharge | 5.1 (3.7 to 6.0) | 5.1 (4.0 to 7.1) | 4.7 (3.7 to 5.9) |
C-Reactive Protein, D-Dimer and Ferritin inflammatory biomarkers were analyzed for this study. Percent Change From Baseline in Inflammatory Biomarkers Over Time were reported here.
| Percent change | Placebo | M5049 50 Milligram (mg) | M5049 100 mg |
|---|---|---|---|
| Percent change at Day 3 in C-Reactive Protein | -0.8 ± 113.57 | 48.2 ± 399.18 | -45.1 ± 59.64 |
| Percent change at Day 7 in C-Reactive Protein | -48.1 ± 69.03 | -50.4 ± 133.43 | -74.3 ± 32.19 |
| Percent change at Day 10 in C-Reactive Protein | 10.5 ± 182.35 | -58.2 ± 43.93 | -68.3 ± 81.09 |
| Percent change at Day 14 in C-Reactive Protein | -62.1 ± 39.95 | 24.6 ± 543.06 | -51.2 ± 159.45 |
| Percent change at Day 28 in C-Reactive Protein | -62.0 ± 91.47 | -27.0 ± 253.69 | -72.4 ± 45.01 |
| Percent change at Day 3 in D-Dimer | 62.5 ± 150.19 | 2008.7 ± 11813.54 | 2093.9 ± 11278.04 |
| Percent change at Day 7 in D-Dimer | 184.5 ± 517.94 | 35.4 ± 197.99 | 1922.7 ± 9449.18 |
| Percent change at Day 10 in D-Dimer | 2004.2 ± 5139.01 | 62.6 ± 202.41 | 171.3 ± 501.83 |
| Percent change at Day 14 in D-Dimer | 1136.7 ± 6760.10 | 0.7 ± 86.62 | 15.1 ± 100.97 |
| Percent change at Day 28 in D-Dimer | 893.4 ± 4731.82 | -5.9 ± 61.09 | 1371.6 ± 6985.20 |
| Percent change at Day 3 in Ferritin | 17.8 ± 83.23 | 3.4 ± 43.05 | -7.2 ± 20.63 |
| Percent change at Day 7 in Ferritin | 11.1 ± 151.34 | -22.7 ± 40.53 | -19.8 ± 27.64 |
| Percent change at Day 10 in Ferritin | 21.4 ± 167.00 | -25.4 ± 31.52 | -39.7 ± 25.13 |
| Percent change at Day 14 in Ferritin | -29.4 ± 117.71 | -47.8 ± 31.56 | -49.9 ± 18.54 |
| Percent change at Day 28 in Ferritin | -61.3 ± 35.83 | -62.3 ± 25.83 | -63.2 ± 15.71 |
Interleukin 6 and Interleukin 8 serum cytokine biomarkers were analyzed. Percent Change From Baseline in Serum Cytokine Biomarkers were reported.
| Percent change | Placebo | M5049 50 Milligram (mg) | M5049 100 mg |
|---|---|---|---|
| Percent change at Day 3 in Interleukin 6 | 51.2 ± 257.64 | -17.8 ± 38.95 | 1722.3 ± 10240.47 |
| Percent change at Day 7 in Interleukin 6 | 35.2 ± 167.99 | 1.1 ± 159.45 | -25.5 ± 42.41 |
| Percent change at Day 14 in Interleukin 6 | 20.2 ± 164.19 | 55.2 ± 476.42 | 275.1 ± 1745.50 |
| Percent change at Day 28 in Interleukin 6 | -21.0 ± 41.33 | -27.3 ± 37.78 | -30.1 ± 36.93 |
| Percent change at Day 3 in Interleukin 8 | 42.5 ± 165.56 | 2.0 ± 77.66 | 126.6 ± 574.74 |
| Percent change at Day 7 in Interleukin 8 | 923.4 ± 4432.63 | 60.2 ± 253.12 | 28.5 ± 113.48 |
| Percent change at Day 14 in Interleukin 8 | 408.9 ± 1776.87 | 35.4 ± 147.85 | 283.5 ± 1616.08 |
| Percent change at Day 28 in Interleukin 8 | -4.3 ± 90.29 | -13.0 ± 59.00 | -1.8 ± 123.62 |
Relapse refers to rehospitalization due to worsening oxygenation, with either a positive result of any respiratory pathogenic nucleic acid test, or worsening lesions on chest imaging.
| Percentage of participants | Placebo | M5049 50 Milligram (mg) | M5049 100 mg |
|---|---|---|---|
| Percentage of Participants With Relapse | 0.0 (0.00 to 7.27) | 0.0 (0.00 to 6.64) | 0.0 (0.00 to 7.71) |
Percentage or participants who are re-hospitalized due to coronavirus disease 2019 (Covid-19) complications were reported.
| Percentage of participants | Placebo | M5049 50 Milligram (mg) | M5049 100 mg |
|---|---|---|---|
| Percentage of Participants Who Are Re-Hospitalized | 0.0 (0.00 to 7.27) | 0.0 (0.00 to 6.76) | 2.2 (0.38 to 11.34) |
Collected over Baseline up to Day 60. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 2/49 (4.1%) | 9/49 (18.4%) | 12/49 (24.5%) |
| M5049 50 Milligram (mg) | 1/54 (1.9%) | 5/54 (9.3%) | 15/54 (27.8%) |
| M5049 100 mg | 0/46 (0%) | 1/46 (2.2%) | 10/46 (21.7%) |
| Event | Placebo | M5049 50 Milligram (mg) | M5049 100 mg |
|---|---|---|---|
| COVID-19Infections and infestations | 3/49 | 4/54 | 0/46 |
| SepsisInfections and infestations | 2/49 | 0/54 | 0/46 |
| Oxygen saturation decreasedInvestigations | 2/49 | 0/54 | 0/46 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/49 | 0/54 | 1/46 |
| AnaemiaBlood and lymphatic system disorders | 1/49 | 0/54 | 0/46 |
| Gastric ulcerGastrointestinal disorders | 1/49 | 0/54 | 0/46 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 1/49 | 0/54 | 0/46 |
| Clostridium difficile infectionInfections and infestations | 1/49 | 0/54 | 0/46 |
| Carpal tunnel syndromeNervous system disorders | 1/49 | 0/54 | 0/46 |
| Acute kidney injuryRenal and urinary disorders | 1/49 | 0/54 | 0/46 |
| Event | Placebo | M5049 50 Milligram (mg) | M5049 100 mg |
|---|---|---|---|
| Alanine aminotransferase increasedInvestigations | 6/49 | 1/54 | 1/46 |
| ConstipationGastrointestinal disorders | 2/49 | 6/54 | 0/46 |
| HypokalaemiaMetabolism and nutrition disorders | 1/49 | 3/54 | 4/46 |
| InsomniaPsychiatric disorders | 4/49 | 1/54 | 1/46 |
| DiarrhoeaGastrointestinal disorders | 0/49 | 4/54 | 0/46 |
| Sinus bradycardiaCardiac disorders | 0/49 | 1/54 | 3/46 |
| RashSkin and subcutaneous tissue disorders | 1/49 | 0/54 | 3/46 |
| Transaminases increasedInvestigations | 1/49 | 3/54 | 1/46 |
Safety analysis set included all participants who had received at least one dose of study intervention.
| Age, Continuous(Years) | Placebo | M5049 50 Milligram (mg) | M5049 100 mg | Total |
|---|---|---|---|---|
| Mean | 48.4 ± 14.09 | 51.0 ± 12.25 | 49.2 ± 12.35 | 49.6 ± 12.87 |
| Sex: Female, Male(Participants) | Placebo | M5049 50 Milligram (mg) | M5049 100 mg | Total |
|---|---|---|---|---|
| Female | 18 | 19 | 14 | 51 |
| Male | 31 | 35 | 32 | 98 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | M5049 50 Milligram (mg) | M5049 100 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 29 | 38 | 29 | 96 |
| Not Hispanic or Latino | 20 | 15 | 15 | 50 |
| Unknown or Not Reported | 0 | 1 | 2 | 3 |
| Race (NIH/OMB)(Participants) | Placebo | M5049 50 Milligram (mg) | M5049 100 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 13 | 16 | 12 | 41 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 1 |
| Black or African American | 3 | 7 | 4 | 14 |
| White | 22 | 20 | 25 | 67 |
| More than one race | 6 | 7 | 0 | 13 |
| Unknown or Not Reported | 4 | 4 | 5 | 13 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website bit.ly/IPD21
Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code
Time frame: Within six months after the approval of a new product or a new indication for an approved product in both the United States and the European Union
Access criteria: Qualified scientific and medical researchers can request the data. Such requests must be submitted in writing to the company's portal and will be internally reviewed regarding criteria for researchers' qualification and legitimacy of the research proposal.
Data sharing details ↗ · bit.ly
Ran from Jul 2020 to primary completion in Aug 2021, 12 months.
Results were first posted in Jun 2022, 9 months after primary completion.
Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 12 months is above that.
Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enpatoran
EMD Serono Research & Development Institute, Inc. →